Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT)

E. Hutson, Thomas; D. Davis, Ian; Machiels, J-P.; L. de Souza, Paul; Hong, Bao; Rottey, Sylvie; L. Baker-Neblett, Katherine; Crofts, T.; Pandite, Lini; A. Figlin, Robert

doi:10.1200/jco.2007.25.18_suppl.5031

Public

Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT)

Published in Journal of Clinical Oncology • Jun 20, 2007

Authors:

Thomas E. Hutson

Ian D. Davis

J-P. Machiels

Abstract

5031 Background: Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit that blocks tumor growth & inhibits angiogenesis. This Phase II RDT determined effects of pazopanib on tumor growth in patients with adv/met RCC a...

Subject

Pazopanib

Medicine

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!